Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crinecerfont phase 3 study in adults with classic congenital adrenal hyperplasia
MOH_2021-12-22_010425Phase 3Not yet recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of crinecerfont in 21-hydroxylase deficiency (21-OHD) (5 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Reduction in daily glucocorticoid dose while maintaining adrenal androgen control. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
crinecerfont
03
Conditions
21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on MOH_2021-12-22_010425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-22_010425.